產(chǎn)品詳情
簡(jiǎn)單介紹:
Nilotinib(AMN-107)
詳情介紹:
Purpose | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). In June 2006, a Phase I clinical trial found nilotinib has a relatively favorable safety profile and shows activity in cases of CML resistant to treatment with imatinib (Gleevec?), another tyrosine kinase inhibitor currently used as a first-line treatment. |
Characteristics |
Tradename: AMN-107 Source of Compound: synthetic Target: Bcr-Abl inhibitor,Mast/stem cell GFR Kit agonist Receptor: Bcr-Abl ,Mast/stem cell GFR Kit Status: FDA |
Purification | All the products are sent with COA, HPLC and NMR inspection report to guarantee the quality. |
Purity | 99.00?% |
Formula | C28H22F3N7O |
Solubility | DMSO 27 mg/Ml,Water <1 mg="" ml="" <="" td=""> 1> |
Molecular Weight | 529.52 g/mol |
CAS-No | 641571-10-0 |
Application Notes | Optimal working dilution should be determined by the investigator. |
Restrictions | For Research Use only |
Format | Solid |
Storage | -20 °C |
Storage Comment |
For the majority of compounds, they could be dissolved in DMSO or other organic solvent. Their stock solution can be stored at -20°C for up to 3 months and aliquoted for sampling convenience. Several freeze/thaw cycles should not damage the activity of our small molecule products. However, in many instances the aqueous solutions of some compounds need to be made fresh and cannot be stored. For these compounds, their solution should be prepared just before use and stored no longer than 24 hours. |
Expiry Date | 24 months |